Literature DB >> 8912474

Review of allelic loss and gain in prostate cancer.

G S Bova1, W B Isaacs.   

Abstract

There are three nearly ubiquitous genomic "imbalances" in prostate cancer cells: 1) loss of sequences from the short arm of chromosomes 8, 2) loss of sequences from the long arm of chromosome 13q, and 3) gain of sequences on the long arm of chromosome 8, particularly in advanced disease. Candidate tumor suppressor genes and oncogenes affected by this trio of consistent changes include the c-myc gene on chromosome 8q24, the RB gene at 13q14, and potentially multiple novel genes on the short arm of chromosome 8, with a gene located more proximally potentially involved in tumor initiation and a gene or genes located more distally involved in tumor progression. Loss of regions of chromosomes 2q, 5q, 6q, 7p and 7q, 9p, 10p and 10q, 16q, 17p and 17q, and 18q, and gain of regions of 1q, 2p, 3p and 3q, 7p and 7q, 11p, 17q, and Xq have also been detected in the range of 25-50% of tumors studied. Analysis of candidate tumor suppressor genes in these regions is still in its early stages. Similarly, potential oncogenes on a series of chromosomal arms which undergo frequent amplification remain essentially uncharacterized. The basic outline of the chromosomal aberrations in prostate cancer has been well established; the details of the story remain to be filled in. This paper reviews the advantages and disadvantages of various techniques for detection of genomic loss and gain in prostate cancer cells, and reviews published reports of loss and gain in prostate cancer, focusing primarily on reports using microsatellite analysis, Southern analysis, and comparative genomic hybridization. Fluorescence in situ hybridization (FISH) based analyses of selected regions are also reviewed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8912474     DOI: 10.1007/bf00184607

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  77 in total

Review 1.  Trisomy 7 in nonneoplastic cells.

Authors:  B Johansson; S Heim; N Mandahl; F Mertens; F Mitelman
Journal:  Genes Chromosomes Cancer       Date:  1993-04       Impact factor: 5.006

2.  Allelotype analysis of esophageal squamous cell carcinoma.

Authors:  I Shibagaki; Y Shimada; T Wagata; M Ikenaga; M Imamura; K Ishizaki
Journal:  Cancer Res       Date:  1994-06-01       Impact factor: 12.701

3.  Human epithelial ovarian cancer allelotype.

Authors:  W Cliby; S Ritland; L Hartmann; M Dodson; K C Halling; G Keeney; K C Podratz; R B Jenkins
Journal:  Cancer Res       Date:  1993-05-15       Impact factor: 12.701

4.  A tumor chromosome rearrangement further defines the 11p13 Wilms tumor locus.

Authors:  L M Davis; B Zabel; G Senger; H J Lüdecke; B Metzroth; K Call; D Housman; U Claussen; B Horsthemke; T B Shows
Journal:  Genomics       Date:  1991-07       Impact factor: 5.736

5.  Cytogenetic analysis of 57 primary prostatic adenocarcinomas.

Authors:  R Lundgren; N Mandahl; S Heim; J Limon; H Henrikson; F Mitelman
Journal:  Genes Chromosomes Cancer       Date:  1992-01       Impact factor: 5.006

6.  Trisomy 8 as a recurrent clonal abnormality in breast cancer?

Authors:  J Bullerdiek; E Leuschner; E Taquia; U Bonk; S Bartnitzke
Journal:  Cancer Genet Cytogenet       Date:  1993-01

7.  Mapping of chromosomal gains and losses in prostate cancer by comparative genomic hybridization.

Authors:  S Joos; U S Bergerheim; Y Pan; H Matsuyama; M Bentz; S du Manoir; P Lichter
Journal:  Genes Chromosomes Cancer       Date:  1995-12       Impact factor: 5.006

8.  Aneuploidy and aneusomy of chromosome 7 detected by fluorescence in situ hybridization are markers of poor prognosis in prostate cancer.

Authors:  A Alcaraz; S Takahashi; J A Brown; J F Herath; E J Bergstralh; J J Larson-Keller; M M Lieber; R B Jenkins
Journal:  Cancer Res       Date:  1994-08-01       Impact factor: 12.701

9.  Deletion mapping reveals two regions of chromosome 8 allele loss in colorectal carcinomas.

Authors:  M L Yaremko; M L Wasylyshyn; K L Paulus; F Michelassi; C A Westbrook
Journal:  Genes Chromosomes Cancer       Date:  1994-05       Impact factor: 5.006

10.  Loss of chromosome arm 8p loci in prostate cancer: mapping by quantitative allelic imbalance.

Authors:  D MacGrogan; A Levy; D Bostwick; M Wagner; D Wells; R Bookstein
Journal:  Genes Chromosomes Cancer       Date:  1994-07       Impact factor: 5.006

View more
  19 in total

Review 1.  Molecular profiling of clinical tissues specimens: feasibility and applications.

Authors:  M R Emmert-Buck; R L Strausberg; D B Krizman; M F Bonaldo; R F Bonner; D G Bostwick; M R Brown; K H Buetow; R F Chuaqui; K A Cole; P H Duray; C R Englert; J W Gillespie; S Greenhut; L Grouse; L W Hillier; K S Katz; R D Klausner; V Kuznetzov; A E Lash; G Lennon; W M Linehan; L A Liotta; M A Marra; P J Munson; D K Ornstein; V V Prabhu; C Prang; G D Schuler; M B Soares; C M Tolstoshev; C D Vocke; R H Waterston
Journal:  J Mol Diagn       Date:  2000-05       Impact factor: 5.568

Review 2.  Molecular profiling of clinical tissue specimens: feasibility and applications.

Authors:  M R Emmert-Buck; R L Strausberg; D B Krizman; M F Bonaldo; R F Bonner; D G Bostwick; M R Brown; K H Buetow; R F Chuaqui; K A Cole; P H Duray; C R Englert; J W Gillespie; S Greenhut; L Grouse; L W Hillier; K S Katz; R D Klausner; V Kuznetzov; A E Lash; G Lennon; W M Linehan; L A Liotta; M A Marra; P J Munson; D K Ornstein; V V Prabhu; C Prange; G D Schuler; M B Soares; C M Tolstoshev; C D Vocke; R H Waterston
Journal:  Am J Pathol       Date:  2000-04       Impact factor: 4.307

3.  A genome screen of families with multiple cases of prostate cancer: evidence of genetic heterogeneity.

Authors:  C L Hsieh; I Oakley-Girvan; R R Balise; J Halpern; R P Gallagher; A H Wu; L N Kolonel; L E O'Brien; I G Lin; D J Van Den Berg; C Z Teh; D W West; A S Whittemore
Journal:  Am J Hum Genet       Date:  2001-06-12       Impact factor: 11.025

4.  PROTEOME-3D: an interactive bioinformatics tool for large-scale data exploration and knowledge discovery.

Authors:  Deborah H Lundgren; Jimmy Eng; Michael E Wright; David K Han
Journal:  Mol Cell Proteomics       Date:  2003-09-07       Impact factor: 5.911

5.  Nuclear C-MYC expression level is associated with disease progression and potentially predictive of two year overall survival in prostate cancer.

Authors:  Wen Zeng; Hanying Sun; Fankai Meng; Zeming Liu; Jing Xiong; Sheng Zhou; Fan Li; Jia Hu; Zhiquan Hu; Zheng Liu
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

6.  MYC and Prostate Cancer.

Authors:  Cheryl M Koh; Charles J Bieberich; Chi V Dang; William G Nelson; Srinivasan Yegnasubramanian; Angelo M De Marzo
Journal:  Genes Cancer       Date:  2010-06

7.  Alterations in nucleolar structure and gene expression programs in prostatic neoplasia are driven by the MYC oncogene.

Authors:  Cheryl M Koh; Bora Gurel; Siobhan Sutcliffe; Martin J Aryee; Denise Schultz; Tsuyoshi Iwata; Motohide Uemura; Karen I Zeller; Uzoma Anele; Qizhi Zheng; Jessica L Hicks; William G Nelson; Chi V Dang; Srinivasan Yegnasubramanian; Angelo M De Marzo
Journal:  Am J Pathol       Date:  2011-04       Impact factor: 4.307

8.  XPC intron11 C/A polymorphism as a risk factor for prostate cancer.

Authors:  Yoshihiro Yoshino; Shouhei Takeuchi; Takahiko Katoh; Yoshiki Kuroda
Journal:  Environ Health Prev Med       Date:  2016-01-08       Impact factor: 3.674

Review 9.  Signal transducer and activator of transcription 5A/B in prostate and breast cancers.

Authors:  Shyh-Han Tan; Marja T Nevalainen
Journal:  Endocr Relat Cancer       Date:  2008-06       Impact factor: 5.678

10.  STAT5A/B gene locus undergoes amplification during human prostate cancer progression.

Authors:  Bassem R Haddad; Lei Gu; Tuomas Mirtti; Ayush Dagvadorj; Paraskevi Vogiatzi; David T Hoang; Renu Bajaj; Benjamin Leiby; Elyse Ellsworth; Shauna Blackmon; Christian Ruiz; Mark Curtis; Paolo Fortina; Adam Ertel; Chengbao Liu; Hallgeir Rui; Tapio Visakorpi; Lukas Bubendorf; Costas D Lallas; Edouard J Trabulsi; Peter McCue; Leonard Gomella; Marja T Nevalainen
Journal:  Am J Pathol       Date:  2013-05-07       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.